摘要
系统性轻链型(AL)淀粉样变性是由异常克隆的浆细胞产生过多的免疫球蛋白轻链,以淀粉样蛋白的形式沉积在身体各个器官,从而导致沉积部位器官的损伤。AL淀粉样变性起病隐匿,临床表现多样,是一种老年群体极易被忽视或误诊的少见疾病,早期病死率较高。AL淀粉样变性的早期诊断和治疗取得深度缓解对患者的长期生存至关重要,本文就老年AL淀粉样变性的治疗现状和新型药物的治疗进展做一下系统综述。
Systemic light-chain(AL)amyloidosis has an insidious onset and diverse clinical manifestations with high early mortality and can be easily overlooked or misdiagnosed in the elderly.Early diagnosis and deep remission are critical for the long-term survival of AL amyloidosis patients.This article provides a systematic review of the current status of treatment and progress in new drugs for AL amyloidosis.
作者
姚庆民
朱效娟
王建春
Yao Qingmin;Zhu Xiaojuan;Wang Jianchun(Department of Geriatric Hematology and Oncology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China;Department of Geriatric Cardiology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China)
出处
《中华老年医学杂志》
CAS
CSCD
北大核心
2021年第10期1337-1341,共5页
Chinese Journal of Geriatrics
基金
国家重点研发项目(2020YFC2008902)
山东省自然科学基金面上项目(ZR2020MH112)。
